课题基金 / 基金详情

Planning a Multicenter Cooling Trial for Hyperammonemic Metabolic Crises

Planning a Multicenter Cooling Trial for Hyperammonemic Metabolic Crises
规划针对高氨代谢危机的多中心冷却试验
批准号:
8445667
负责人:
Uta Lichter-Konecki
金额:
$16.92万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-01-01 至 2014-03-31

项目摘要

项目成果

Uta Lichter-Konecki的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):本R34提案的目的是制定一项方案和程序手册,用于在尿素循环障碍(UCD)或有机酸中毒(OAs)导致的高氨血症相关脑病的幼儿中进行治疗性低温作为辅助治疗的随机临床试验。对于试验中这些罕见和非常复杂的患者,各研究中心的共识对于治疗的一致性至关重要。在为期一年的资助期间,我们将努力在19个参与研究中心就这些儿童的整体治疗方案达成共识,这些儿童将接受核心辅助低温、代谢和肾脏替代治疗。然后,我们将完成方案并编写程序手册(MOP)。我们还将标准化各研究中心高级神经影像学数据的收集,以便在试验期间测试其作为结局生物标志物的效用。患有高氨血症(HA)相关脑病和UCD或OA的新生儿有很大的神经损伤、发育障碍和死亡风险。在20世纪80年代,尽管进行了积极的血液透析治疗,但因尿素循环完全阻滞而出现HA和昏迷的新生儿死亡率接近50%。在接受治疗的存活儿童中,79%有一种或多种发育障碍。残疾程度与新生儿昏迷时间显著相关。同样,新生儿OAs伴HA相关脑病的死亡率为33%或更高。1987年引入氨清除剂治疗慢性UCD改善了尿素循环障碍患者的长期治疗结果。然而,尽管在重症监护和血液透析方面取得了进展,但在随后的十年中,1991年至2000年期间,在一家主要三级医疗中心,患有严重UCD或OAs的儿童因初始高氨血症危象的死亡率仍超过50%,超过40%的幸存者表现出相当大的智力残疾。因此,对于患有最严重形式的UCD和OAs的新生儿或幼儿,要真正受益于长期治疗和肝移植的进步,并获得更好的生活质量,需要一种新的神经保护性干预措施来改善初始危机的结果。根据小型临床研究的结果,治疗性低温(TH)可能构成这样的神经保护疗法。在其成为非循证的常见做法之前,明确研究其对HA相关脑病的疗效非常重要。在一个明确定义的患者组中进行测试,可以得出其他HA相关脑病患者的结论。未来随机对照试验的目的是评估全身TH作为HA相关脑病新生儿和幼儿标准治疗的辅助神经保护治疗的有效性和安全性。
英文摘要
DESCRIPTION (provided by applicant): The objective of this R34 proposal is to develop a protocol and manual of procedures for the conduct of a randomized clinical trial of therapeutic hypothermia as adjunct therapy in young children with hyperammonemia associated encephalopathy resulting from urea cycle disorders (UCDs) or organic acidemias (OAs). Consensus across sites will be critical for uniformity of treatment in these rare and very complex patients in the trial. During this one year grant we will work to build consensus across the 19 participating sites regarding the overall treatment protocol for these children that will have at is core adjunct hypothermia, metabolic and renal replacement therapy. We will then finalize the protocol and write the Manual of Procedures (MOP). We will also standardize the collection of advanced neuroimaging data across sites so that their utility as biomarkers for outcome can be tested during the trial. Newborns with hyperammonemia (HA) associated encephalopathy and UCDs or OAs are at great risk for neurological injury, developmental disability, and death. In the 1980s the mortality of neonates that presented with HA and in coma due to complete blocks in the urea cycle approached 50%, despite aggressive treatment with hemodialysis. Of the surviving children on therapy, 79% had one or more developmental disability. The degree of disability was significantly correlated to the duration of neonatal coma. Similarly, the mortality f neonatal OAs with HA associated encephalopathy was 33% and higher. The introduction of ammonia scavenger therapy for the chronic treatment of UCDs in 1987 improved outcome of long-term treatment for patients with urea cycle disorders. However, despite advances in intensive care and hemodialysis, over the subsequent decade mortality of children with severe UCDs or OAs still exceeded 50% for an initial hyperammonemic crisis at a major tertiary care medical center between 1991 and 2000 and more than 40% of survivors showed considerable intellectual disability. Thus, for neonates or young infants with the most severe forms of UCDs and OAs to truly benefit from the advances in long-term treatment and from liver transplant and to have a better quality of life, a novel, neuroprotective intervention is needed to improve the outcome of the initial crisis. Based on the results of small clinical studies, therapeutic hypothermia (TH) may constitute such a neuroprotective therapy. It is important to investigate its efficacy for HA associated encephalopathy definitively before it becomes common practice that is not evidence-based. Testing this in a well defined group of patients should allow to draw conclusions for other patients with HA associated encephalopathy. The purpose of the future randomized controlled trial will be to assess the efficacy and safety of whole body TH as adjunct neuroprotective therapy to standard of care treatment of neonates and young infants with HA associated encephalopathy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
LONGITUDINAL STUDY OF UREA CYCLE DISORDERS
  • 批准号:
    8167341
  • 项目类别:
  • 资助金额:
    $1.96万
  • 财政年份:
    2010
  • 负责人:
    Uta Lichter-Konecki
  • 依托单位:
WIRB - A PHASE 2, FIXED-SEQUENCE, OPEN-LABEL, SWITCH-OVER STUDY OF THE
  • 批准号:
    8167309
  • 项目类别:
  • 资助金额:
    $1.22万
  • 财政年份:
    2010
  • 负责人:
    Uta Lichter-Konecki
  • 依托单位:
LONGITUDINAL STUDY OF UREA CYCLE DISORDERS
  • 批准号:
    7951104
  • 项目类别:
  • 资助金额:
    $3.24万
  • 财政年份:
    2008
  • 负责人:
    Uta Lichter-Konecki
  • 依托单位:
LONGITUDINAL STUDY OF UREA CYCLE DISORDERS
  • 批准号:
    7717192
  • 项目类别:
  • 资助金额:
    $1.57万
  • 财政年份:
    2007
  • 负责人:
    Uta Lichter-Konecki
  • 依托单位:
海外基金